Roche Bets $5.3B on Amylin Drug Petrelintide to Shake Up Obesity Market
The obesity drug market, already red-hot from the success of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, just got hotter.…
Tag: GLP-1
Eli Lilly’s Mounjaro (Tirzepatide) Targets Emerging Markets: A Game-Changer for Global Obesity?
Eli Lilly and Company, a global pharmaceutical leader, announced plans to launch its blockbuster weight-loss drug Mounjaro (tirzepatide) in emerging markets by…
Understanding the Different Types of Obesity: A Comprehensive Guide
Obesity is not a one-size-fits-all condition. It manifests in diverse ways, influenced by factors like fat distribution, underlying causes, and…
Scientists Discover CD44: A Potential New Weapon Against Obesity
In the relentless battle against obesity, scientists have uncovered a surprising new player: the protein CD44. Groundbreaking research published in The American…
Liraglutide in 2025: Diabetes, Weight Loss, and New Updates
Key Highlights What is Liraglutide? Liraglutide is a GLP-1 receptor agonist, a class of medications revolutionizing type 2 diabetes treatment…
Next Up in Obesity Drugs: A Timeline of What’s Coming to Market (2026–2028+)
The fight against obesity is entering an exciting new era. With blockbuster drugs like Wegovy (semaglutide) and Zepbound (tirzepatide) already…
Myostatin’s Role in the Next Weight-Loss Revolution
Key Points Background Current weight-loss methods, including lifestyle changes, surgery, and drugs like Wegovy and Zepbound, often result in both…